EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

 

 

As part of MPE’s Year of Action, we are excited to announce the launch of the survey on myeloma and AL amyloidosis diagnosis. At MPE, we know that early diagnosis significantly improves the outcomes and quality of life of patients and their experience of healthcare.


The survey seeks to understand the perspectives of myeloma and AL amyloidosis patients, as well as haematologists, on the diagnosis challenges. The survey will take approximately 5 minutes to complete and is available in 26 European languages.
 

Click here to take part in the survey.
 

We encourage you to share the link on your webpage, social media platforms and with your networks to help us get as many responses as possible. MPE will use the survey results to inform the work we do to advocate for equal access to a timely diagnosis for all patients.

 

To learn more about MPE’s Year of Action and our ongoing activities, please click here.

 







Recent news

» EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myeloma

» Study shows myeloma caregivers experience higher levels of anxiety than the patients they support

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy